Genelux Corporation (GNLX) vs Insight Molecular Diagnostics Inc. (IMDX)
A side-by-side comparison of Genelux Corporation and Insight Molecular Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GNLX
Genelux Corporation
$2.54HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
IMDX
Insight Molecular Diagnostics Inc.
$3.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GNLX vs IMDX
growth of $100 · dividends reinvested · last 4yGNLX -57.7% (-19.4%/yr)IMDX -60.1% (-20.5%/yr)GNLX compounded faster over this window
GNLX IMDX
GNLX vs IMDX: by the numbers
- •GNLX is the larger company ($114M vs $109M market cap).
- •Both run net losses; IMDX's is the smaller (-2955.63% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | GNLX | IMDX |
|---|---|---|
| P/S ratio | 14236.83 | 65.35 |
| P/B ratio | 7.07 | N/A |
Profitability
| Metric | GNLX | IMDX |
|---|---|---|
| Gross margin | -7075.00% | 11.17% |
| Operating margin | -415175.00% | -754.08% |
| Net margin | -422412.50% | -2955.63% |
| ROE | -209.73% | N/A |
| ROIC | -192.18% | -223.06% |
Growth (annualized)
| Metric | GNLX | IMDX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 27.24% |
| Total return CAGR (5Y) | N/A | -44.39% |
Go deeper
Dig into the metrics
Genelux ROEInsight Molecular Diagnostics ROEGenelux operating marginInsight Molecular Diagnostics operating marginGenelux revenue growthInsight Molecular Diagnostics revenue growthGenelux free cash flowInsight Molecular Diagnostics free cash flow
Genelux & Insight Molecular Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.